Core Insights - EVA Pharmaceuticals and Zhejiang Jinhua Conba Biopharmaceutical Group have signed a strategic supply agreement to enhance cross-border cooperation in the healthcare sector, aiming to build a more resilient and accessible medical supply chain [1][3] Group 1: Strategic Partnership - The agreement was signed during the 2025 CPHI China event, representing high-level collaboration between two influential companies in their respective regions [3] - The partnership aims to support a more sustainable, flexible, and secure pharmaceutical supply chain, ultimately increasing accessibility for patients in emerging markets [3] - Both companies are committed to long-term supply reliability, technological excellence, and patient-centered delivery models [3] Group 2: Company Profiles - EVA Pharmaceuticals focuses on improving global access to affordable, high-quality medicines, emphasizing innovation, development, and sustainable accessibility [4] - The company operates four internationally recognized manufacturing facilities, producing over one million medical products daily, with a workforce of over 5,000 professionals [4] - EVA Pharmaceuticals' product portfolio targets twelve therapeutic areas, including infectious diseases, metabolic health, oncology, and pediatrics, addressing both local and international health needs [4] Group 3: Market Impact - The collaboration is expected to set a new benchmark for trust-based cross-border supply cooperation amid growing global demand for supply chain resilience [3] - The partnership combines EVA Pharmaceuticals' regional coverage with Conba's manufacturing capabilities to create a sustainable impact in key markets [3]